



Thiogenesis Therapeutics Corp.

Symbol: TSXV: TTI | OTCQX: TTIPF

Sector: Biotechnology

Purpose: Raise Awareness / Open Market Buying

Thiogenesis is a clinical-stage biopharmaceutical company focused on developing sulfur-based prodrugs for serious pediatric conditions. The Company's experienced leadership team has successfully brought several drugs to market, including major launches on NASDAQ. TTI-0102 is currently undergoing Phase 2 trials for MELAS. Additional Phase 2 studies are planned for Leigh syndrome and pediatric MASH, and a key Phase 3 trial for cystinosis has recently been announced.

Investor Bullet Points:

TTI-0102 unlocks the potential of cysteamine by eliminating its historical limitations

- Cysteamine demonstrates proven potential as a treatment for diseases with billion dollar addressable markets; however, its development has been impeded by GI side effects.
- TTI-0102 (controlled-release) has already shown significantly improved tolerability at much higher doses with a novel sulfur-based prodrug design, as verified in Phase 1 trials.
- The Company is preparing for a Phase 3 cystinosis trial - where a less effective version of the compound is already approved and has an ongoing Phase 2 EU trial for MELAS, a rare mitochondrial disorder without approved treatments.
- The company presents an attractive valuation and considerable upside compared to its rare disease peers, which trade at multiples of 5-10x relative to Thiogenesis.

Brook Riggins, CFA, Director & CFO

Mr. Riggins has more than 25 years of experience in small-cap public markets, focusing on biotechnology, medical technology, and emerging technologies. He has held senior financial and strategic positions at investment firms and listed life sciences companies. Notably, he led the RTO and public listing of Thiogenesis' predecessor, Raptor Pharmaceutical (NASDAQ: RPTP), which was acquired for US\$800 million in 2016.